Abstract
The role of dopamine in sleep-wake regulation is considered as a wakefulness-promoting agent. For the clinical treatment of excessive daytime sleepiness, drugs have been commonly used to increase dopamine release. However, sleep disorders or lack of sleep are related to several dopaminerelated disorders. The effects of dopaminergic agents, nevertheless, are mediated by two families of dopamine receptors, D1 and D2-like receptors; the first family increases adenylyl cyclase activity and the second inhibits adenylyl cyclase. For this reason, the dopaminergic agonist effects on sleep-wake cycle are complex. Here, we review the state-of-the-art and discuss the different effects of dopaminergic agonists in sleep-wake states, and propose that these receptors account for the affinity, although not the specificity, of several effects on the sleep-wake cycle.
Keywords: Dopamine, dopamine agonist, sleep-wake states, wakefulness-promoting agents, receptors, nuclei.
Graphical Abstract
CNS & Neurological Disorders - Drug Targets
Title:Dopaminergic Modulation of Sleep-Wake States
Volume: 16 Issue: 4
Author(s): Andrea Herrera-Solis, Wendy Herrera-Morales, Luis Nunez-Jaramillo and Oscar Arias-Carrion*
Affiliation:
- Unidad de Trastornos del Movimiento y Sueño (TMS). Hospital General Dr. Manuel Gea González, Avenida Calzada de Tlalpan 4800, Tlalpan, Sección XVI, Ciudad de México, C.P. 14080,Mexico
Keywords: Dopamine, dopamine agonist, sleep-wake states, wakefulness-promoting agents, receptors, nuclei.
Abstract: The role of dopamine in sleep-wake regulation is considered as a wakefulness-promoting agent. For the clinical treatment of excessive daytime sleepiness, drugs have been commonly used to increase dopamine release. However, sleep disorders or lack of sleep are related to several dopaminerelated disorders. The effects of dopaminergic agents, nevertheless, are mediated by two families of dopamine receptors, D1 and D2-like receptors; the first family increases adenylyl cyclase activity and the second inhibits adenylyl cyclase. For this reason, the dopaminergic agonist effects on sleep-wake cycle are complex. Here, we review the state-of-the-art and discuss the different effects of dopaminergic agonists in sleep-wake states, and propose that these receptors account for the affinity, although not the specificity, of several effects on the sleep-wake cycle.
Export Options
About this article
Cite this article as:
Herrera-Solis Andrea, Herrera-Morales Wendy , Nunez-Jaramillo Luis and Arias-Carrion Oscar *, Dopaminergic Modulation of Sleep-Wake States, CNS & Neurological Disorders - Drug Targets 2017; 16 (4) . https://dx.doi.org/10.2174/1871527316666170320145429
DOI https://dx.doi.org/10.2174/1871527316666170320145429 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mygalin: A New Anticonvulsant Polyamine in Acute Seizure Model and Neuroethological Schedule
Central Nervous System Agents in Medicinal Chemistry Targeting Angiogenic Genes as a Therapeutic Approach for Hepatocellular Carcinoma
Current Gene Therapy Folic Acid, Neurodegenerative and Neuropsychiatric Disease
Current Molecular Medicine Alzheimer´s Disease and Oxidative Stress: A Review
Current Medicinal Chemistry Voltammetric Investigation and Determination of Piribedil in Pharmaceutical Dosage Forms Using Carbon-Based Electrodes
Current Pharmaceutical Analysis Preface
Current Pharmaceutical Design Insulin-like Effects of Mt. Fuji Subsoil Water which Conta ins Vanadium on Cultured Cells: Insight from Japan
Current Traditional Medicine Glycodendrimer PPI as a Potential Drug in Chronic Lymphocytic Leukaemia. The Influence of Glycodendrimer on Apoptosis in In Vitro B-CLL Cells Defined by Microarrays
Anti-Cancer Agents in Medicinal Chemistry Cytochrome P450 Regulation and Drug Biotransformation During Inflammation and Infection
Current Drug Metabolism Recent Advances in Obesity Pharmacotherapy
Current Clinical Pharmacology T Lymphocytes as Targets of Statins: Molecular Mechanisms and Therapeutic Perspectives
Inflammation & Allergy - Drug Targets (Discontinued) Chemistry and Pharmacology of Angiotensin-Converting Enzyme Inhibitors
Current Pharmaceutical Design The Epidemiology and Health Effects of Tobacco Smoke Exposure
Current Pediatric Reviews Novel Treatment Strategies for the Nervous System: Circadian Clock Genes, Non-coding RNAs, and Forkhead Transcription Factors
Current Neurovascular Research EDITORIAL: New Psychoactive Substances (NPS), a New Global Issue: Neuropharmacological, Chemical and Toxicological Aspects
Current Neuropharmacology Coordination of Ribosomal Protein and Ribosomal RNA Gene Expression in Response to TOR Signaling
Current Genomics Moving to the Rhythm with Clock (Circadian) Genes, Autophagy, mTOR, and SIRT1 in Degenerative Disease and Cancer
Current Neurovascular Research Platelet-derived Growth Factor Receptor-beta is Differentially Regulated in Primary Mouse Pericytes and Brain Slices
Current Neurovascular Research Targeting Transcription Factor Binding to DNA by Competing with DNA Binders as an Approach for Controlling Gene Expression
Current Topics in Medicinal Chemistry Meet Our Editorial Board Member
Current Neuropharmacology